Preview

Онкологическая колопроктология

Расширенный поиск

ВЫБОР ТАРГЕТНОГО ПРЕПАРАТА ВО ВТОРОЙ ЛИНИИ ТЕРАПИИ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ТОЛСТОЙ КИШКИ

https://doi.org/10.17650/2220-3478-2015-1-37-42

Полный текст:

Аннотация

За последние 5 лет значимо выросла выживаемость больных метастатическим раком толстой кишки (мРТК). Это обусловлено не только активным внедрением хирургического удаления метастазов и применением таргетных препаратов в 1-й линии терапии, но и тем, что все большему числу пациентов проводится 2-я и последующие линии эффективного системного лечения. В настоящее время внедрение новых таргетных препаратов в 1-й линии терапии привело к формированию как минимум 7 ле- чебных групп в зависимости от того, что получал пациент в 1-й линии. Поэтому, если ориентироваться на постулаты доказательной медицины, стало труднее определиться с наиболее эффективным лечением во 2-й линии в каждой данной группе больных. Именно сложности выбора таргетных препаратов во 2-й линии терапии у больных с мРТК и посвящен настоящий обзор.

Об авторах

М. Ю. Федянин
ФГБНУ «РОНЦ им. Н.Н. Блохина»
Россия

ФГБНУ «РОНЦ им. Н.Н. Блохина»; Россия, 115478, Москва, Каширское шоссе, 24

 

 



А. А. Трякин
ФГБНУ «РОНЦ им. Н.Н. Блохина»
Россия
ФГБНУ «РОНЦ им. Н.Н. Блохина»; Россия, 115478, Москва, Каширское шоссе, 24


С. А. Тюляндин
ФГБНУ «РОНЦ им. Н.Н. Блохина»
Россия
ФГБНУ «РОНЦ им. Н.Н. Блохина»; Россия, 115478, Москва, Каширское шоссе, 24


Список литературы

1. Tournigand С., André T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229–37.

2. Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005 Dec 20;23(36):9441–2.

3. Schmoll H.J., Van Cutsem E., Stein A. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012 Oct;23(10): 2479–516.

4. Giantonio B.J., Catalano P.J., Meropol N.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr 20;25(12):1539–44.

5. Tamagawa H., Iwamoto S., Takahashi T. et al. FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin based therapy: The randomized phase III EAGLE study. JCO suppl. ASCO 2013, abs 3516.

6. Hong Y.S., Kim H.J., Park S.J. et al. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Cancer Sci 2013 Apr;104(4):473–80.

7. Sobrero A.F., Maurel J., Fehrenbacher L. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008 May 10;26(14):2311–9.

8. Seymour M.T., Brown S.R., Middleton G. et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild- type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013 Jul;14(8):749–59.

9. Peeters M., Price T.J., Cervantes A. et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second- line treatment of metastatic colorectal cancer. Ann Oncol 2014 Jan;25(1):107–16.

10. Peeters M., Oliner K.S., Price T.J. et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3568).

11. Élez E., Kocáková I., Höhler T. et al. Abituzumab combined with cetuximab plus irinotecan as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer: The POSEIDON phase I trial/ randomized phase II trial. Ann Oncol 2014;25(suppl 4):iv167–209.

12. Beretta G.D., Petrelli F., Stinco S. et al. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol 2013 Mar;30(1):486.

13. Van Cutsem E., Dicato M., Geva R. et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011 Jun; 22 Suppl 5:v1–9.

14. Chau I., Joulain F., Iqbal S.U., Bridgewater J. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer 2014;14:605. doi: 10.1186/1471-2407-14-605.

15. Pericay C., Folprecht G., Saunders M. et al. Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM). Ann Oncol 2012;23(Suppl 4):iv16, abstr. 0024.

16. Grothey A., Sugrue M.M., Purdie D.M. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008 Nov 20;26(33):5326–34.

17. Bendell J.C., Bekaii-Saab T.S., Cohn A.L. et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17(12):1486–95.

18. Bennouna J., Sastre J., Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013 Jan;14(1):29–37.

19. Masi G., Loupakis F., Salvatore L. et al. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO). J Clin Oncol 2013;31:15 (suppl; abstr 3615).

20. Kopetz S., Hoff P.M., Morris J.S. et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010 Jan 20;28(3):453–9.

21. Loupakis F., Cremolini C., Fioravanti A. et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011 Apr 12;104(8):1262–9.

22. Masi G., Loupakis F., Salvatore L. et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first- line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845–52.

23. Tabernero J., Cohn A.L., Obermannova R. et al. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 2015;33(suppl 3; abstr 512).

24. Heinemann V., von Weikersthal L.F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065–75.

25. Modest D.P., Stintzing S., von Weikersthal L.F. et al. Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial. J Clin Oncol 2014;32:5s (suppl; abstr 3558^).

26. Rivera F., Schwartzberg L.S., Karthaus M. et al. Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3629).


Для цитирования:


Федянин М.Ю., Трякин А.А., Тюляндин С.А. ВЫБОР ТАРГЕТНОГО ПРЕПАРАТА ВО ВТОРОЙ ЛИНИИ ТЕРАПИИ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ТОЛСТОЙ КИШКИ. Онкологическая колопроктология. 2015;5(1):37-42. https://doi.org/10.17650/2220-3478-2015-1-37-42

For citation:


Fedyanin M.Y., Tryakin A.A., Tjulandin S.A. CHOICE OF TARGETED DRUG FOR SECOND-LINE METASTATIC COLON CANCER CHEMOTHERAPY. Colorectal Oncology. 2015;5(1):37-42. (In Russ.) https://doi.org/10.17650/2220-3478-2015-1-37-42

Просмотров: 382


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2220-3478 (Print)
ISSN 2413-0583 (Online)